By: Maurie Markman, MD
Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline
By: Christin L. Melton, ELS
During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.
By: Danielle Ternyila
Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.